Skip to main content

cnty-101

·Code: CNTY-101

cnty-101: 2 clinical trials tracked.

cnty-101 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about cnty-101, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trial Registry Records (2)

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028Registry updated 2026-01-08·Phase 1·IPSC
Active, not recruiting

Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs

Interventionalopen6 targetStarted 2025-02Completion 2028-086 sites · United StatesCentury Therapeutics, Inc.

The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies

NCT05336409Registry updated 2025-12-18·Phase 1·IPSC
Terminated

Primary endpoint: Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity

Interventionalopen28 targetStarted 2023-01Completion 2025-0716 sites · United StatesCentury Therapeutics, Inc.